Summary
In 25 patients, who received repeated doses of cis-DDP, we determined iodo-131-hippurate-clearance, creatinine clearance and serum creatininc to assess the nephrotoxic effect induced by cis-DDP. A highly significant decrease in the iodo-131-hippurate-clearance was found between the first and the following cycles. There was no significant change in serum creatinine and creatinine clearance however. The radio-hippurate-clearance showed a clinically not important reduction during several cytotoxic courses in 15/25 patients (60%). A clinically relevant impairment of the radio-hippurate-clearance occurred in 8/25 patients (32%), mainly before the third and fifth cytotoxic cycle. In two patients this clearance did not alter or was even rising. In 12 cases a diminuation of the iodo-131-hippurate-clearance was observed, which in only 5 cases correlated to a decreased creatinine clearance and in only two cases to an elevated serum creatinine. Therefore, we consider neither creatinine nor creatinine clearence nor the combination of both parameters to be appropriate to assess tubular nephropathy induced by cis-DDP. Radio-hippurate-clearance should play a superior role deciding on treatment stop or dose reduction of cis-DDP. The regression of cis-DDP-induced nephropathy was not evaluated.
Similar content being viewed by others
Literatur
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group Study. Cancer Treat Rep 66:31–35
Caradonna R, Paladine W, Ruckdeschel JC, Goldstein JC, Olson JE, Jaski JW, Silvers SA, Hillinger S, Horton J (1979) Methotrexate, bleomycin and high-dose cis-dichlorodiammineplatinum (II) in the treatment of advanced epidermoid carcinoma of the head and neck. Cancer Treat Rep 63:489–491
Cohen AI, Harberg J, Citrin DL (1981) Measurement of urinary beta-2-microglobulin in the detection of cisplatin nephrotoxicity. Cancer Treat Rep 65:1083–1085
Comis RL (1980) Cisplatin Nephrotoxicity: The effect of dose, schedule, and hydration scheme. In: Prcstayko AW, Crooke ST, Carter SK (eds) Cisplatin. Academic Press, New York, pp 485–494
Einhorn LH, Donohue JP (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298
Fleming JJ, Collis C, Peckham MJ (1979) Renal damage after cis-platinum. Lancet II:960
Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362–1371
Hacke M, Alt J, Schmoll HJ, Stolte H (1981) Nephrotoxizität von cis-Platin mit und ohne Ifosfamid in der Behandlung maligner Hodentumoren. Verh Dtsch Ges Inn Med 87:1114–1117
Hayes DM, Cvitkovic E, Gollbey RB, Scheiner E, Helson L, Krakoff IH (1977) High Dose cis-Platinum Diammine Dichloride. Cancer 39:1372–1381
Hör G, Papst HW (1979) Nephrologie. In: Emrich D (Hrsg) Nuklearmedizin Funktionsdiagnostik und Therapie. Thieme, Stuttgart, 2. Aufl, S 332–380
Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal Handling of cis-Diamminedichloroplatinum (II). Cancer Treat Rep 64:1223–1225
Jones B, Mladck J, Bhalla R, Reidenberg M, Schwartz M, Young C (1979) Enzymuria and beta-2-Microglobulinuria as sensitive indices of cisplatinum nephrotoxicity. Proc Am Assoc Cancer Res 20:336
Kunkel R, Oberhausen E (1971) Radiation doses in renal clearance studies. IAEA Symposium: On the assessment of radioactive organ and body burdens. Stockholm (IAEA/SM-150/26)
Meijer S, Mulder NH, Sleijfer DT, de Jong PE, Sluiter WJ, Schraffordt Koops H, van der Hem GK (1982) Nephrotoxicity of cis-Diamminedichloride Platinum (CDDP) During Remission-induction and Maintenance Chemotherapy of Testicular Carcinoma. Cancer Chemother Pharmacol 8:27–30
Nirenberg A, Cacavio A, Bru G, Caparros B, Rosen G (1981) Ambulatory high dose cisplatinum (HD-DDP) with mannitol diuresis: A treatment system without renal, auditory or biochemical toxicity. Proc Am Assoc Cancer Res 22:528
Oberhausen E, Kunkel R, Emrani J, Thocz R (1970) Funktionsuntersuchungen mit teilabgeschirmtem Ganzkörperzähler. In: Radioaktive Isotope in Klinik und Forschung. Urban und Schwarzenberg, München, S 181
Panettiere FJ (1981) Cis-Platinum (CACP) Toxicity. Proc Am Assoc Cancer Res 22:157
Pecking A, Mehdaoui A, Delorme G, Coornaert S, Oglobine J, Merlin L, Debaud B (1982) Quantitative renal cinescintigraphy with orthoiodohippurate I-123: Application to investigation of renal tubular toxicity under cis-dichlorodiammine platinum. Preliminary results. In: Raynaud C (ed) Proc 3rd World Congress Nucl Med Biol. Pergamon, Paris, p 573
Pixberg HU, Just G (1971) Die Bestimmung des effektiven Plasmastroms mit der 131-Jod-Hippursäure-Ganzkörperclearance. Dtsch Med Wochenschr 96:156–161
Prestayko AW, Luft C, Einhorn L, Crooke ST (1978) Cisplatin pharmacokinetics in a patient with renal dysfunction. Med Pediatr Oncol 5:183–188
Randolph VL, Wittes RE (1978) Weekly Administration of Cis-Diamminedichloroplatinum (II) without Hydration or Osmotic Diuresis. Eur J Cancer 14:753–756
Reubi F (1970) Nierenkrankheiten. Huber, Bern, 3. Auflage, S 396–401
Rohloff R, Hast B, Leisner B, Heinze HG (1975) Bestimmung der 131-Jod-Hippuran-Clearance im Rahmen der Kamerafunktionsszintigraphie der Nieren nach vereinfachten Modifikationen der Methode von Oberhausen. Nucl Med 13:303–322
Schilsky RL (1982) Renal and Metabolic Toxicities of Cancer Chemotherapy. Semin Oncol 9:75–83
Stark JJ, Howell SB (1978) Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 23:461–465
Author information
Authors and Affiliations
Additional information
Herrn Prof. Dr. med. J. Lissner zum 60. Geburtstag gewidmet
Rights and permissions
About this article
Cite this article
Wendt, T.G., Hartenstein, R., Büll, U. et al. Die 131-Jod-Hippuranclearance zur Erfassung der nephrotoxischen Wirkung von cis-Dichlorodiamino-Platin (II) (cis-Platin, cis-DDP). Klin Wochenschr 61, 561–566 (1983). https://doi.org/10.1007/BF01486846
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01486846